Analyst: Darzalex sales could reach top end of projections
Janssen’s recently published sales figures for cancer drug Darzalex indicate a promising year-end result is in store, according to a Sydbank analyst.
by marketwire, translated by daniel pedersen
On Tuesday, Genmab saw a bad stock market start turn around after its partner, US-based pharmaceutical firm Johnson & Johnson, released its first quarter figures for 2022, which revealed a sales advancement for bone marrow cancer drug Darzalex.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen's sales of Darzalex exceed expectations
For subscribers
